News for Healthier Living

Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis

Concerto Biosciences(r), a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for mild-to-moderate atopic dermatitis (AD).

October 28, 2025


October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025

October 22 2025

October 21 2025

October 20 2025

October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025

October 14 2025